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As medicine advances toward a more personalized 
model, the significance of genetic information is growing 
exponentially. While unlocking the genetic code has 
advanced the state of medicine, it has also reinvigorated 
the debate over the boundaries of patentable subject 
matter. The potential clash between having access to state-
of-the-art medicine and protecting intellectual property 
investments came to a head in the case, Association of 
Molecular Pathology v. USPTO (“Myriad”). This Article 
analyzes the legal opinion rendered by the district court 
through the unique lens of genetic exceptionalism—a 
concept previously reserved to social science and public 
policy. Then, this Article analyzes Judge Sweet’s 
unprecedented incorporation of genetic exceptionalism into 
the Patent Act by first tracing the historical roots of the 
exceptionalism doctrine and then dissecting the Myriad 
decision through that historical lens. As it stands at 
publication, it has yet to be seen whether the Supreme 
Court will similarly adopting a novel interpretation of the 
* Kristen L. Burge has a B.S. in Neuroscience from Vanderbilt University 
and a J.D. from Cumberland School of Law. After graduating magna cum laude 
from Cumberland, Kristen went on to earn an LL.M. in Intellectual Property 
Law and Policy at the University of Washington School of Law. Kristen is 
currently a member in good standing of the Washington State Bar Association. 
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Patent Act that incorporates genetic exceptionalism into 
the Act’s subject matter restrictions. 
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Judge Sweet’s decision in Association of Molecular Pathology 
v. USPTO (“Myriad”)1 has reinvigorated the longstanding debate 
of whether genes qualify for patent protection and whether 
granting such protection does more harm to patients than good for 
innovation. In a health care system moving more toward 
personalized medicine, the resolution of these questions is vital for 
the stability—and possibly the survival—of genetic innovation. 
Myriad has the potential to greatly impact the way personalized 
medicine is administered to patients by increasing access to more 
at-risk patients and decreasing the cost of genetic testing. On the 
other hand, the decision could be a potential setback to genetic 
innovation that results in more harm to patients by stifling research 
incentives. Regardless, stakeholders on both sides of the debate are 
eagerly awaiting the appeal that will provide some stability in an 
unsettled area of patent law.  
There is no disagreement that since its discovery, DNA has 
captivated audiences from the science, medical, ethical, and legal 
fields, at times rising DNA to a near-reverent status. Despite the 
promise that genetic science holds, the science is susceptible to 
abuse, as has been demonstrated by the history of eugenics and 
1 702 F. Supp. 2d 181 (S.D.N.Y. 2010). The procedural history of this 
case—following Judge Sweet’s opinion in district court—is complicated. The 
Federal Circuit first affirmed in part and reversed in part the lower court’s 
decision in Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 
653 F.3d 1329 (Fed. Cir. 2011) (reversing the lower court’s decision on gene 
patentability by holding, among other things, that human genes are eligible 
patent matter). Certiorari was granted by the United States Supreme Court, only 
to have the case remanded back to the Federal Circuit for reconsideration. See 
Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 (2012). 
After the Federal Circuit reviewed the case, the Supreme Court again granted 
certiorari, limiting the issue to whether human genes are patentable. See Ass’n 
for Molecular Pathology v. U.S. Patent and Trademark Office, 689 F.3d 1303 
(Fed. Cir. 2012) and Ass’n for Molecular Pathology v. Myriad Genetics, Inc, 
133 S. Ct. 694 (Nov. 30 2012) (certiorari granted in part). As it stands, the 
parties have until March 2013 to file their briefs on the merit. For an up-to-date 
status of the case as it proceeds through the Supreme Court, visit the case on the 
Scotus Blog, available at http://www.scotusblog.com/case-files/cases/ 
association-for-molecular-pathology-v-myriad-genetics-inc/.  
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ethnically targeted genetic screening programs. It is this 
unharnessed power to do both good and bad that has directed 
scientists, academia, and policy makers alike to treat genetic 
information differently than other scientific knowledge, resulting 
in “genetic exceptionalism.” Until the Myriad decision, however, 
genetic exceptionalism did not exist as a legal principle under the 
Patent Act, but was instead relegated to areas of discrimination, 
privacy, and insurance.  
To better understand Myriad’s impact on personalized 
medicine and the progeny of gene patents flowing from the 
genome, it is helpful to first understand basic genetic science, the 
development of genetic exceptionalism in other contexts, the 
various types of gene patents, and the existing law on subject 
matter patentability. Part I of this Article begins with an overview 
of personalized medicine and its relation to genetic science. Parts 
II and III discuss the impact of patenting these genetic tools and 
the types of patent protection falling within the catch-all category 
of “gene patents.” In Part IV, the Article provides a summary of 
the precedent governing the subject matter patentability 
requirement. Finally, Part V addresses Judge Sweet’s incorporation 
of genetic exceptionalism into the Patent Act by first tracing the 
historical roots of the exceptionalism doctrine and then dissecting 
the Myriad decision through that historical lens. After doing so, the 
Article concludes that the court in Myriad inappropriately adopted 
genetic exceptionalism as a legal principle on patentability instead 
of leaving the gene patent policy decision to Congress.  
 
I. CHANGING THE FACE OF MEDICINE ONE STRAND AT A TIME:  
HOW GENETIC INFORMATION IS ALTERING THE PRACTICE OF 
MEDICINE 
 
A.  Defining Personalized Medicine 
 
What does the ambiguous phrase “personalized medicine” 
actually mean? After all, doctor-patient relationships have 
traditionally been of a personal nature. New advances in 
technology have altered this traditional doctor-patient approach to 
4
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treatment2 and solidified “personalized medicine” as a term of art. 
Building on the traditional doctor-patient relationship, personalized 
medicine moves health care one step further by providing 
physicians with a more precise tool to evaluate, diagnose, and treat 
patients. Beyond promising better health outcomes for individual 
patients, personalized medicine also has the potential to transform 
the entire health care delivery infrastructure into a more efficient, 
cost-effective system.3 
Despite being a recognized term of art, “personalized 
medicine” has multiple definitions. On the literal end of the 
spectrum, personalized medicine refers to the development of stem 
cell based therapies that are specifically tailored to an individual.4 
In this context, doctors would use cloned stem cells—embryonic or 
adult—to generate additional cells, tissues, or organs to circumvent 
the inherent risks associated with individual transplantations.5 
On the other end of the spectrum, personalized medicine is cast 
more broadly, referring to technologies and treatments that can be 
administered to a subset of the population based on common 
characteristics found in DNA and environmental factors. More in 
line with this broader definition, the Personalized Medicine 
2 See, e.g., Kent Bottles, The Doctor/Patient Relationship for the 21st 
Century, THE PHYSICIAN EXECUTIVE 10-14 (Sep.-Oct. 2001), available at 
http://www.kentbottles.com/pdfs/Doctor-Patient-Relationship-for-the-21st-
Century.pdf (discussing different views of the doctor/patient relationship).  
3 See generally James P. Evans et. al., Preparing for a Consumer-Driven 
Genomic Age, 363 NEW ENG. J. MED. 1099 (2010) (discussing personalized 
health care in the direct-to-consumer genetic testing context); Eric D. Green & 
Mark S. Guyer, Charting a Course for Genomic Medicine from Base Pairs to 
Bedside, 470 NATURE 204 (February 2011) (discussing a 2011 vision for 
moving towards an era of genomic medicine); Margaret A. Hamburg & Francis 
S. Collins, The Path to Personalized Medicine, 363 NEW ENG. J. MED. 301 
(2010) (discussing the hurdles in moving from concept to clinical use); The Case 
for Personalized Medicine, PERSONALIZED MEDICINE COALITION, 
http://cllcanada.ca/2010/pdfs/TheCaseforPersonalizedMedicine_5_5_09.pdf 
(discussing the benefits of personalized medicine and the necessary steps for 
widespread implementation). 
4 See Matthew Herder, Patents & the Progress of Personalized Medicine: 
Biomarkers Research as Lens, 18 ANNALS HEALTH L. 187, 190-91 (2009). 
5 Id. at 190. Currently embryonic stem cell therapy is in its nascent stage 
and not a realistic therapeutic option. 
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Coalition describes the emerging practice as follows: 
Personalized medicine uses new methods of 
molecular analysis to better manage a patient’s 
disease or predisposition toward a disease. It aims 
to achieve optimal medical outcomes by helping 
physicians and patients choose the disease 
management approaches likely to work best in the 
context of a patient’s genetic and environmental 
profile. Such approaches may include genetic 
screening programs that more precisely diagnose 
diseases and their sub-types, or help physicians 
select the type and dose of medication best suited to 
a certain group of patients.6 
Other definitions go even further to dispel the potential 
misunderstanding surrounding the term “personalized.” For 
instance, the President’s Council of Advisors on Science and 
Technology stressed that personalized medicine “does not literally 
mean the creation of drugs or medical devices that are unique to a 
patient but rather the ability to classify individuals into 
subpopulations that differ in their susceptibility to a particular 
disease or their response to a specific treatment.”7 
In other words, personalized medicine interpreted broadly 
enables physicians to provide better diagnoses and earlier 
interventions, to engage in more effective drug development, and 
to implement more effective therapies for various subsets of 
patients who share the same genetic variations.8 
 
 
6 Personalized Medicine: An Introduction, PERSONALIZED MEDICINE 
COALITION, http://www.personalizedmedicinecoalition.org/sites/default/files/ 
personalmed_backgrounder.pdf. 
7 Priorities for Personalized Medicine, President’s Council of Advisors on 
Science and Technology (September 2008), http://www.whitehouse.gov/ 
files/documents/ostp/PCAST/pcast_report_v2.pdf. 
8 Id. Because this paper focuses primarily on gene patents, the term 
personalized medicine should be understood in the broader context as defined by 
the Coalition and the President’s Council. 
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B.  The Science Underlying Genetics and Personalized Medicine 
 
Genetic science continues to revolutionize the practice of 
medicine by enabling treatment tailored to individual patients and 
providing insight to better therapeutic approaches. Although many 
patients utilize personalized medicine at some point over the 
course of their medical treatment, not all patients understand the 
science behind such treatment. While understanding the basics of 
genetic science and the types of patents currently available for the 
countless discoveries in the field would aid the reader’s 
understanding of the genetic impact on medicine, an in-depth 
discussion of this complex science is beyond the scope of this 
paper.9 Instead, this Article will provide a basic explanation from a 
patient’s perspective: what are genes and how are they patented? 
This section will define the key terms and introduce the basic 
scientific foundations of genetics, moving into an overview of the 
various categories of patents that collectively are referred to as 
“gene patents.”  
The genomic structure is best understood by explaining the 
different parts of DNA and how its components direct the 
formation of proteins.10 DNA (deoxyribonucleic acid) is a double 
helix structure created by two chemically-bonded strands that 
9 See, e.g., Alan E. Guttmacher & Francis S. Collins, Genomic Medicine – A 
Primer, 347 N. ENG. J. MED. 1512-20 (2002); W. Gregory Feero & Alan E. 
Guttmacher, Genomic Medicine – An Updated Primer, 362 N. ENG. J. MED. 
2001-11 (2010); Wylie Burke, Genetic Testing, 347 N. ENG. J. MED. 1867-75 
(2002). 
10 Many articles go into great detail on the structure of DNA and its 
corresponding science. See, e.g., Eric D. Zard, Note, Patentability of Human 
Genetic Information: Exploring Ethical Dilemmas Within the Patent Office and 
Biotechnology’s Clash with the Public Good, 6 U. ST. THOMAS L.J. 486-490 
(2009); Lorelei Perez Westin, Note, Genetic Patents: Gatekeeper to the 
Promised Cure, 25 T. JEFFERSON L. REV. 271, 276-79 (2002). Similarly, the 
Federal Circuit has discussed molecular genetics in greater depth. See, e.g., In re 
Deuel, 51 F.3d 1552, 1554-56 (Fed. Cir. 1995); Amgen, Inc. v. Chugai Pharm. 
Co., Ltd., 927 F.2d 1200, 1207-08 (Fed. Cir. 1991); In re O’Farrell, 853 F.2d 
894, 895-99 (Fed. Cir. 1988). This Article will not rearticulate the scientific 
foundation in as great detail, but will rather provide sufficient background to 
understand the gene patents and their relationship with genetic exceptionalism.  
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stores and encodes an organism’s genetic information.11 Each 
DNA strand contains four base molecules (A, G, C, and T) that 
serve as the building blocks.12 Before the cell can make the 
protein, the DNA strand must undergo three processes: (1) copying 
the DNA strand into RNA (transcription); (2) removing or splicing 
of the inactive regions (introns) and connecting the active regions 
(exons); and (3) translating the RNA (ribonucleic acid) into its 
corresponding amino acids.13 When joined together, these amino 
acids fold into unique three-dimensional shapes that determine the 
property and function of the protein in the body.14 
While the human genome contains more than three billion base 
pairs,15 only two percent of these base pairs represent the 20,000 to 
25,000 genes present in the human genome.16 In comparing human 
11 Wylie Burke, Genetics Primer, NATIONAL ASSOCIATION OF WOMEN 
JUDGES, GENOME JUSTICE, September 2005, 1-14. 
12 Id. 
13 The following figure, a reproduction of Figure 14.5 from DAVID KROGH, 
BIOLOGY: A GUIDE TO THE NATURAL WORLD 249 (5th ed., 2005), depicts the 
two processes for decoding genetic information: 
 
14 There are typically three regions that are relevant to genetic patents: (1) 
the exon region (coding region of the gene); (2) the promoter and terminating 
regions of a gene (which mark the beginning and the end of gene); and the (3) 
intron region (non-coding regions that are spliced or removed during the 
transcription phase). See Mark A. Chavez, Gene Patenting: Do the Ends Justify 
the Means, 7 COMPUTER L. REV. & TECH. J. 255, 256 (2003). 
15 The human genome refers to the complete set of DNA from the combined 
chromosomes. See The Science Behind the Human Genome Project: Basic 
Genetics, Genome Draft Sequence, and Post-Genome Science, HUMAN GENOME 
PROJECT INFORMATION (Mar. 26, 2008) http://www.ornl.gov/sci/techresources/ 
Human_Genome/project/info.shtml. 
16 How Many Genes Are in the Human Genome?, HUMAN GENOME 
PROJECT INFORMATION (Sept. 19, 2008) http://www.ornl.gov/sci/techresources/ 
Human_Genome/faq/genenumber.shtml. Currently, the average gene is 
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genomes, scientists have discovered that humans share 
approximately 99.9 percent of the same code, resulting in only .01 
percent variation between human genomes.17 Scientists have 
identified 1.4 million locations where these single-base variations 
occur.18 These variations are referred to as single nucleotide 
polymorphisms, or “SNPs.”19 
Depending on where the variation occurs, the mutation(s) may 
result either in minor changes that account for the normal range of 
characteristic like hair color, height, or medication response, or in 
more profound changes that are responsible for various forms of 
genetic diseases.20 While a single mutation may cause a handful of 
diseases, the majority of diseases are multifactorial, depending on 
a complex interaction of multiple genes and numerous 
environmental factors.21 
 
II. PATENTING THE TOOLS OF PERSONALIZED MEDICINE:  
A LOOK AT THE IMPACT OF GENETIC PATENTS ON PATIENT CARE 
 
Each step towards understanding the human genome fortifies 
the bridge between DNA code and a patient’s bedside by creating 
new possibilities in personalized medicine. With the completion of 
the Human Genome Project, researchers have unlocked the key to 
a wealth of genetic information. But discovering the function and 
relationship of genes and translating these discoveries into 
approximately 3,000 bases, with the largest known gene having 2.4 million. And 
of the known genes, scientists can identify the function for only approximately 
50 percent. 
17 Burke, supra note 9, at 4. 
18 Id. 
19 Id. 
20 Id. SNPs help determine the likelihood that a person will develop a 
disease during his or her lifetime. 
21 See id. at 7, 12. The media coverage has influenced the public’s 
perception of genetic diseases, often oversimplifying the causation between a 
mutation and a disease and overemphasizing the determinative effect of a 
genetic mutation. Diseases caused by single gene mutations can be broken down 
into autosomal dominant, autosomal recessive, and X-linked recessive disorders. 
Chromosomal conditions, another subset of genetic diseases, are caused by a 
deficiency or excess of chromosomal material. Id. at 9-11. 
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beneficial treatment is an ongoing, complex endeavor. Currently, 
there are over 6,000 diseases that can be traced to a single gene,22 
while there are thousands of other conditions that are linked to 
genetic variations in multiple genes and interactions with 
environmental factors. As scientists better understand these 
complex genetic interactions, further progress can be made in the 
development of diagnostic tools, prevention techniques, and 
therapeutic treatments.23 
With the progress in personalized medicine comes the desire to 
protect the intellectual property associated with such 
advancements. The impetus behind the U.S. patent law system has 
always been the careful balancing between the competing interests 
of incentivizing innovation, encouraging the disclosure of 
inventions for the public good, and fostering competition. The 
framers of the U.S. Constitution were mindful of these tradeoffs in 
drafting Article I § 8, which provides that Congress shall have the 
power “[t]o promote the Progress of Science and useful Arts, by 
securing for limited Times to Authors and Inventors the exclusive 
Right to their respective Writings and Discoveries.”24 America’s 
founding fathers understood that granting an exclusive right for a 
period of time may justify an otherwise undesired monopoly so 
long as the exclusive right provided sufficient incentives to invest 
in research and development that would otherwise not come to 
fruition absent the incentive. In exchange for this period of 
exclusivity, however, the patentee must contribute to the public a 
useful, novel, non-obvious invention–disclosing sufficient 
information for a person skilled in the arts to practice the 
invention.25 
Understanding that innovation and ongoing discovery is 
22 Melissa Conrad Stoppler, Genetic Diseases Overview, 
MEDICINENET.COM (May 11, 2010), http://www.medicinenet.com/ 
genetic_disease/article.htm. 
23 Eric D. Green & Mark S. Guyer, Charting a Course for Genomic 
Medicine from Base Pairs to Bedside, 470 NATURE 204 (2011); see also Ethical, 
Legal & Social Issues: Gene Testing, HUMAN GENOME PROJECT INFORMATION 
(July 7, 2010) http://www.ornl.gov/sci/techresources/Human_Genome/elsi/ 
patents.shtml. 
24 U.S. CONST. art. I, § 8, cl. 8. 
25 See 35 U.S.C. §§101-103, 112 (2003). 
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imperative to personalized medicine’s success, numerous 
stakeholders have raised concerns that granting genetic patents 
may substantially impede necessary scientific research and block 
access to therapeutic treatments.26 As a basis for these public 
policy concerns, critics argue that the twenty years of protection 
provided to the patent holder from the date of filing enables the 
patent holder to prevent others from researching the patented gene 
and from performing diagnostic testing procedures on patented 
variations of the gene.27 Critics maintain that even if a patent 
holder is willing to license the patent(s), researchers have a 
difficult time locating the owner of the patent rights.28 Moreover, 
because U.S. patent law permits patent issuance for gene fragments 
and single nucleotide variations (see discussion on the types of 
gene patents, infra), critics argue that licensees incur higher 
transaction costs to obtain multiple licenses associated with one 
gene.29 
In an effort to assess whether gene patents truly inhibit 
research, health and science researcher David Blumenthal30 
conducted several surveys that targeted both academics and 
commercial scientists involved with genetic research. He found 
that “[o]ne of every five medical scientists has delayed publication 
of research results for at least half a year in order to protect 
26 See Marisa Noelle Pins, Impeding Access to Quality Patient Care and 
Patient Rights: How Myriad Genetics’ Gene Patents Are Unknowingly Killing 
Cancer Patients and How to Calm the Ripple Effect, 17 J. INTELL. PROP. L. 377 
(2010). 
27 See Eric Zard, Comment, Patentability of Human Genetic Information: 
Exploring Ethical Dilemmas Within the Patent Office and Biotechnology’s 
Clash With the Public Good, 6 U. ST. THOMAS L.J. 486, 504 (2009). 
28 Id. 
29 Id. 
30 David Blumenthal, M.D., M.P.P., was appointed on March 20, 2009, by 
the Obama Administration to serve as the National Coordinator for Health 
Information Technology. In this capacity, Dr. Blumenthal will lead “the 
implementation of a nationwide interoperable, privacy-protected health 
information technology infrastructure.” U.S. Dept. of Health & Human Services, 
HHS Names David Blumenthal As National Coordinator for Health Information 
Technology (March 20, 2009), available at http://www.hhs.gov/news/ 
press/2009pres/03/20090320b.html.  
                                                                                                             
11
Burge: Personalized Medicine, Genetic Exceptionalism, and the Rule of La
Published by UW Law Digital Commons, 2013
512 WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS  [VOL. 8:4 
financial interests.”31 He also found that “twenty-eight percent of 
the geneticists surveyed reported that they were unable to duplicate 
published research because other academic scientists refused to 
share information, data, or materials,”32 thereby preventing 
scientists from verifying the studies.  
Further compounding the problem of gene patents is the 
“patent thicket”—a term critics use to refer to the multiple patents 
on various components of a gene—which, according to some 
critics, “may be stifling life-saving innovations further downstream 
in the course of research and product development.”33 In other 
words, if research scientists must acquire multiple licenses from 
multiple parties to conduct research on any given gene, then the 
cost of researching gene therapy is greater and the research itself is 
at risk of being derailed by a patent holder who refuses to license a 
necessary input to the research.34 
While some critics concede that a level of patent protection is 
necessary for incentivizing research, they suggest that the patent 
system is offering protection at the wrong stage in the development 
process.35 By issuing patents early in the development process 
when little is understood about the role the gene plays, a patent 
holder can assert the patent against later discovered mutations or 
genetic associations when more is understood about the gene’s role 
in genetic diseases.36 Arguably, the patent system grants the 
equivalent of a “hunting license” to the pioneering scientist, 
rewarding the search without compensating later discoveries that 
31 Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial 
Incentives With Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65, 81 (2002) 
(summarizing findings in David Blumenthal et al., Withholding Research 
Results in Academic Life Sciences, 277 JAMA 1224, 1224 (1997)).  
32 Id. (citing David Blumenthal et al., Data Withholding in Academic 
Genetics, 284 JAMA 473, 477 (2002)). 
33 Id. at 85 (quoting Michael A. Heller and Rebecca S. Eisenberg, Can 
Patents Deter Innovation? The Anticommons in Biomedical Research, 280 SCI. 
698, 701 (1998)). 
34 See id. at 85-86. 
35 See id. 
36 See id. at 87-88. But consider that some people, including Steven Shavell, 
argue that awarding patents early in the process prevents excess duplicative 
investment. 
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result in a useful application.37 As Justice Abraham Fortas once 
summarized, “a patent may confer power to block off whole areas 
of scientific development, without compensating benefits to the 
public.”38  
Finally, gene patents arguably deprive patients the access to 
reliable genetic tests and therapies that would otherwise be 
available. Because some patent holders exclusively license their 
patent, a genetic test may be permitted at one laboratory, leaving 
the patient with no means for getting a second opinion. 
 
III. GENE PATENTS: DOES ONE SIZE FIT ALL? 
 
This Article’s genetic primer has focused thus far on how DNA 
works in its natural, non-patentable state. To be patentable, an 
inventor must “transform” genetic information into a non-natural 
form to circumvent the rule against patenting products of nature.39 
After taking steps to isolate, purify, or modify the genetic 
information, the inventor can claim the resulting product as an 
invention because the resulting product is chemically different 
from the product in nature.40 In other words, the patent is not 
issued on the gene found in the body, but rather on man-made 
DNA molecules.41 
Generally, genetic patent claims relate to one of the following 
four categories found to satisfy the patentability standards prior to 
Myriad:  
(1) Whole genes or parts of them, (2) proteins that 
the genes encode as well as their function in 
organisms, (3) vectors used for the transfer of genes 
37 Id. at 88. 
38 Id. at 88 (quoting Brenner v. Manson, 383 U.S. 519, 536 (1966)). 
39 See, e.g., Parker v. Flook, 437 U.S. 584 (1978); Diamond v. Diehr, 450 
U.S. 175 (1981). 
40 Id. Isolating DNA refers to the process of removing the DNA from its 
natural environment in the body, while purifying DNA refers to removing the 
non-coding regions of the DNA (e.g. cDNA). See John Conley & Dan Vorhaus, 
When the Grass Eats the Cows, 23 GENEWATCH 8 (Oct.-Dec. 2010). 
41 See Sharon Terry, Why Banning Patents Would Hurt Patients, 23 
GENEWATCH 24 (Oct.-Dec. 2010). 
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from one organism to another, or (4) genetically 
modified cells or organisms, processes used for the 
making of genetically modified products and the 
uses of genetic sequences or proteins for genetic 
tests.42 
The patents are generally issued as “compositions of matter” or 
“method-of-use” patents, and although sometimes erroneously 
interpreted as patenting the gene itself, the patent only covers 
genetic information that has been isolated and purified.43  
 
A.  cDNA Patents 
 
Complementary DNA (cDNA) is a synthetic copy of an 
isolated section of DNA that includes only the coding-region for a 
protein as opposed to the entire gene as it is found in the body.44 
Scientists take the mRNA (which is copied DNA minus the non-
coding regions) and convert it into a new DNA molecule through 
reverse transcription (cDNA).45 Structurally and functionally 
different from genes found in nature, cDNA molecules can be used 
to produce large quantities of human protein in non-human species, 
to identify disease-causing mutations for diagnostic testing, to treat 
genetic disorders (gene therapy), and to enable new discoveries 
with their use as chemical reagents and research tools.46 Although 
critics of cDNA patents assert that the information contained in 
cDNA is identical to naturally occurring DNA, even those critics 
acknowledge that naturally occurring DNA cannot be used for 
commercial diagnostic testing and research.47 
42 E. Richard Gold & Julia Carbone, Myriad Genetics: In the Eye of the 
Political Storm, http://www.theinnovationpartnership.org/data/ieg/documents/ 
cases/TIP_Myriad_Legal.pdf (working document). 
43 Id. 
44 See Kevin Noonan, Why Genes Must Remain Eligible for Patenting, 23 
GENEWATCH, 24, 30 (Oct.-Dec. 2010). 
45 Id. 
46 See Terry, supra note 41. 
47 See Magdalina Gugucheva, The Physical Embodiment of Information, 23 
GENEWATCH 26-27 (Oct.-Dec. 2010). Vectors, which are larger molecules with 
integrated cDNA, that can be used to insert genes into other cells, are also 
patentable. 
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B.  EST Patents 
 
Expressed sequence tags (ESTs) are fragments of the cDNA 
molecule that are approximately 300-500 base pairs long, 
representing approximately 10 to 30 percent of the average cDNA 
molecule.48 In practice, ESTs are used as research tools to map and 
discover entire genes in a fraction of the time it would take without 
the aid of these markers. Advocates for EST patenting claim that 
there are several uses for ESTs, which include: (1) serving as a 
molecular marker for mapping genomes; (2) measuring the level of 
mRNA in a tissue sample; (3) providing primers for polymerase 
chain reaction processes; (4) identifying polymorphisms; (5) 
isolating promoters via chromosome walking; (6) controlling 
protein expression; and (7) locating genetic molecules of other 
plants and organisms.49 In 2005, the Federal Circuit addressed the 
patentability of ESTs in In re Fisher.50 Focusing on the utility 
requirement under § 101 of the Patent Act, the court invalidated 
the patent for lacking “specific and substantial utility.”51 Without 
digressing into a utility discussion, it is sufficient for this Article’s 
purpose to understand that EST patents must claim a known 
correlation between the EST and an identified underlying gene to 
be patentable.52 Strictly speaking, the EST must be more than a 
mere research intermediary with no immediate, well-defined 
benefit to the public.53 
 
C.  SNP Patents 
 
Of the patents that are collectively referred to as “gene 
patents,” SNP patents are arguably the most controversial because 
48 Genetics and Patenting, HUMAN GENOME PROJECT INFORMATION (July 7, 
2010) http://www.ornl.gov/sci/techresources/Human_Genome/elsi/ 
patents.shtml. 
49 See In re Fisher, 421 F.3d 1365, 1369-74 (Fed. Cir. 2005) (discussing the 
uses for ESTs proffered by Fisher). 
50 Id. 
51 Id. 
52 See id. at 1372-73. 
53 Id. 
                                                                                                             
15
Burge: Personalized Medicine, Genetic Exceptionalism, and the Rule of La
Published by UW Law Digital Commons, 2013
516 WASHINGTON JOURNAL OF LAW, TECHNOLOGY & ARTS  [VOL. 8:4 
SNP patents permit the patentee to claim one “letter” of a sentence. 
As previously discussed, SNPs are unlike cDNA and EST 
fragments because they represent a genetic mutation (or variation) 
in only one nucleotide base in a genetic sequence.54 These minor 
variations can have a major impact on the way that humans 
respond to disease, environmental factors, or pharmaceuticals and 
medical treatment.55 Typically, SNP patents include claims for the 
method of determining a patient’s susceptibility to a disease by 
detecting a particular SNP in a known gene and for the isolated 
SNP molecule itself.56 
 
D.  Patents on DNA Tests 
 
The relationships between genetic mutations and diseases 
allow practitioners to tailor medical diagnoses and treatment to 
individual patients. Once a gene is discovered, scientists then work 
to develop a complementary test to screen individuals for the 
genetic mutation associated with a disease.57 Genetic tests offer a 
window to a person’s genetic make-up, making it possible to 
confirm suspected diagnoses, to predict likelihood of future illness, 
to detect carrier status in unaffected individuals, and to evaluate a 
person’s response to medical treatment.58 The tests differ in the 
manner by which they identify genetic variations. For example, 
some tests utilize short pieces of DNA, called probes, to seek out a 
complementary sequence to the mutated gene which then binds to 
the sequence if present.59 Another type of genetic testing directly 
compares the patient’s DNA sequence to a normal version of the 
sequence, looking for any differences between the two 
sequences.60 Finally, other genetic tests detect gene products, such 
54 See Genome Project Information, Ethical, Legal & Social Issues: Gene 




57 Genetic Testing, NATIONAL HUMAN GENOME RESEARCH INSTITUTE (Jan. 
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as an enzymes or proteins, for determining whether a gene 
variation is present.61 Beyond method patents for analyzing a 
person’s DNA, genetic testing patents may also cover the physical 
testing kits that contain the necessary materials to perform the 
test.62 
 
E.  Patents on DNA Diagnostic Algorithms 
 
Genetic patents have also been issued for algorithms that 
compare known risks with multiple genetic variations.63 These 
method patents straddle the line between an abstract idea and an 
invention.64 When the algorithm uses information derived from 
multiple variations and gives different weight to known risks, the 
algorithm is likely to be patentable subject matter.65 In this case, 
scientists can invent around the patented algorithm by creating a 
different model of analysis.66 The issue of patentability is more 
questionable when the diagnostic algorithms use an “assay-and-
correlate” model, which analyzes simple levels of physiological 
substances.67 For these algorithms, it much more difficult—if not 
impossible—to design around the patented method. 
 
61 Id. 
62 Eileen M. Kane, Patent-Mediated Standards in Genetic Testing, 2008 
UTAH L. REV. 835, 846 (2008). 
63 Michael J. Shuster & Pauline Farmer-Koppenol, Patent Strategy for 






67 Id. Algorithms are also used in developing synthetic DNA with computer 
software and are patentable. For example, “patents have already been granted on 
many of the processes and products involved in synthetic biology, including 
patents on methods for building synthetic DNA, synthetic genes and DNA 
sequences, synthetic pathways, synthetic proteins and amino acids, and novel 
nucleotides that replace the letters of DNA.” Eric Hoffman & Jaydee Hanson, 
Synthetic Biology: The Next Wave of Patents on Life, 23 GENEWATCH 39, 40 
(Oct.-Dec. 2010). 
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IV. GENETICS AND THE LAW: AN OVERVIEW OF SUBJECT  
MATTER PATENTABILITY PRECEDING MYRIAD 
 
The watershed case invalidating Myriad Genetics’ gene patents 
was not the first to address gene patents, albeit perhaps the first to 
directly attack the patents under the subject matter requirement.68 
Patent law’s history is fraught with cases that courts can draw on 
for the gene patentability analysis, dating as far back as the late 
1800s.69 The earlier cases addressing biotechnology patents 
focused primarily on the novelty and obviousness prongs of 
patentability.70 It was not until after the Patent Act of 1952, 
however, that courts recognized the requirements of subject matter, 
novelty, and non-obviousness were wholly separate inquiries.71 
The purification doctrine72 has long been the linchpin for 
justifying gene patents. In 1874, the Supreme Court addressed the 
validity of a patent on purified cellulose used to make paper.73 The 
Court reasoned that because the product was not substantially 
different than the naturally occurring product either in form or 
substance, the patent was invalid for lack of novelty.74  
Subsequent courts interpreted this decision to mean that 
inventors could potentially patent purified or isolated products of 
nature with a new commercial or therapeutic use. In the early 
1900s, Parke-Davis & Co. v. Kalo Inoculant Co., decided whether 
purified adrenaline could be patented.75 In upholding the validity 
68 Myriad Genetics is the company that holds the patents on BRCA1/2, 
which are the patents the plaintiff sought to invalidate in the case referred to 
herein as Myriad.  
69 See Ashley McHugh, Invalidating Gene Patents: Association for 
Molecular Pathology v. U.S. Patent & Trademark Office, 62 HASTINGS SCI. & 
TECH. L.J. 185, 191-92 (2010). 
70 See id. 
71 See id. 
72 The purification doctrine states that naturally occurring substances may 
still be patentable, despite being products of nature, if the substance can be 
isolated and purified from its naturally occurring state. See, e.g., Parke-Davis & 
Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911). 
73 American Wood-Paper Co. v. Fibre Disintegrating Co., 90 U.S. 566 
(1874). 
74 Id. at 593-96. 
75 Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (S.D.N.Y. 1911). 
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of the patent, the court reasoned that although the product was 
naturally occurring, the purified version of adrenaline was “a new 
thing commercially and therapeutically.”76  
Despite the trend of expansive subject matter, the Supreme 
Court reigned in the scope of patentable subject matter for 
naturally occurring products in its 1948 opinion in Funk Brothers 
Seed Co. v. Kalo Inoculant Co.77 At issue in Funk Brothers was 
the validity of a patent held for a mixture of isolated bacterium, 
which unlike its predecessor products, could be mixed without the 
inhibitory effects owing to the inventor’s method of testing and 
selecting noninhibitive strains.78 The Court evaluated the patent 
under the requirements set forth in 35 U.S.C. § 31, which 
permitted issuance of a patent to, “[a]ny person who has invented 
or discovered any new and useful art, machine, manufacture, or 
composition of matter . . . .”79 Interpreting the requirement of 
“invention or discovery,” Justice Douglas provided that “[t]he 
qualities [of the invention at issue] are the work of nature. Those 
qualities are, of course, not patentable. For patents cannot issue for 
the discovery of the phenomena of nature.”80 The Court focused on 
the properties of the bacterium, namely that they performed no 
new function when mixed together and merely provided a more 
efficient means of packaging for the purchaser.81 
Although seemingly supporting the position that genes (and 
fragments) are entirely outside the scope of patentability as 
products of nature, Justice Douglas’ oft-quoted statement for this 
proposition must be narrowly read in light of the limited question 
presented: whether the mixture was an “invention or discovery” 
within the meaning of 35 U.S.C. § 31. The way the act was written, 
the “invention or discovery” requirement stands separate from the 
patentable subject matter requirement, which is embodied in the 
76 Id. at 103. 
77 333 U.S. 127 (1948). 
78 Id. at 130-31. 
79 35 U.S.C. § 31 (2000) (emphasis added). 
80 Funk Brothers, 333 U.S. at 130. 
81 Id. at 131-32 (“[T]he packages of mixed inoculants also hold advantages 
for the dealers and manufacturers by reducing inventory problems and the 
like.”). 
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“art, machine, manufacture, or composition of matter” language. 
The Court also provided additional language that suggests it was 
not deciding the case on the subject matter prong of patentability:  
Each of the species of root nodule bacteria 
contained in the package infects the same group of 
leguminous plants which it always infected. No 
species acquires a different use. The combination of 
species produces no new bacteria, no change in the 
six species of bacteria, and no enlargement of the 
range of their utility. . . . Their use in combination 
does not improve in any way their natural 
functioning.82 
Because the Funk Brothers analysis was directed at the 
invention or discovery prong—not the subject matter prong—the 
holding should be narrowly construed in subsequent cases.83 
Opponents of gene patents should not be quick to conclude that the 
case prohibits patenting naturally occurring biological products 
since the likely correct interpretation invalidates only those patents 
that fail to apply the naturally occurring substance in a non-
obvious way.84 
Indeed, Funk Brothers did not foreclose the door for patents on 
naturally occurring substances despite Justice Douglas’ 
“phenomena of nature” reasoning.85 In 1980, the Supreme Court 
82 Id. at 131 (emphasis added). 
83 See id. at 132 (“[W]e conclude that the product claims do not disclose an 
invention or discovery within the meaning of the patent statutes, we do not 
consider whether the other statutory requirements contained in 35 U.S.C. § 31, 
R.S. § 4886, are satisfied.”) (emphasis added). 
84 See John M. Conley & Roberte Makowski, Back to the Future: 
Rethinking the Product of Nature Doctrine as a Barrier to Biotechnology 
Patents, 85 J. PAT. & TRADEMARK OFF. SOC'Y 301 (2003). 
85 See, e.g., Merck & Co. v. Olin Mathieson Chemical Corp., 253 F.2d 156, 
164 (4th Cir. 1958). In 1958, the Fourth Circuit Court of Appeals upheld a 
patent on purified vitamin B-12 based on the therapeutic and commercial value 
of the biological product, noting that nothing in the language of the Patent Act 
of 1952 prohibited the patenting of naturally occurring substances. Id. The court 
found that compositions of matter necessarily included products of nature, 
stating: 
All of the tangible things with which man deals and for which 
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decided the question whether a genetically modified organism was 
patentable subject matter under the current Patent Act, 35 U.S.C. § 
101.86 Drawing from the purification doctrine, the Supreme Court 
held that a genetically altered organism was patentable as a 
“nonnaturally occurring” biological product.87 The Court reasoned 
that the genetically engineered bacterium—developed to break 
down oil—was patentable under § 101 as a “manufacture” or 
“composition of matter” because the altered product had 
characteristics that did not exist in its native environment.88 
Specifically distinguishing Funk Brothers, the Chakrabarty Court 
held that the bacterium had “markedly different characteristics 
from any found in nature and one having the potential for 
significant utility.”89 Unlike in Funk Brothers, the Chakrabarty 
decision clearly speaks to the subject matter requirement. 
Marking a turning point for the biotechnology industry, 
Chakrabarty has since provided gene patent advocates with fodder 
in the patentability debate.90 By the close of the 20th century, the 
patentability of isolated (or purified) naturally occurring products 
was well-established, providing the biotechnology industry with 
much-needed assurance that its emerging discoveries would be 
protected by the U.S. patent system.91 The USPTO issued 
numerous gene patents under the purification doctrine without 
dispute as to whether the subject matter was beyond the scope of 
patentability, granting over 5,000 DNA patents and 16,000 relating  
 
 
patent protection is granted are products of nature in the sense 
that nature provides the basic source materials. The ‘matter’ of 
which patentable new and useful compositions are composed 
are composed necessarily includes naturally existing elements 
and materials. 
Id. at 161-62. 
86 Diamond v. Chakrabarty, 447 U.S. 303 (1980). 
87 Id. at 303. 
88 See id. at 308-09. 
89 Id. at 310. 
90 See Gold, supra note 42; DAVID B. RESNIK, OWNING THE GENOME: A 
MORAL ANALYSIS OF DNA PATENTING 1 (2004). 
91 See id. 
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to DNA in the two decades that followed this revolutionary 
decision.92  
Despite the proliferation of DNA patents, none have been 
invalidated for lack of subject matter. Instead, challenges to gene 
patents focus primarily on the novelty, utility, and non-obviousness 
requirements for patentability.93 
 
V. BEGGING THE QUESTION: DOES GENETIC EXCEPTIONALISM  
HAVE A PLACE IN THE PATENT ACT? 
 
A.  The History of Genetic Exceptionalism in Social Science and 
Public Policy 
 
Several bioethicists and legal commentators have discussed the 
role of genetic exceptionalism in the areas of privacy, insurance, 
and discrimination laws, with some questioning whether the 
special treatment of genetic information is necessary or even 
beneficial.94 Despite the body of literature replete with arguments 
for and against gene patentability, genetic exceptionalism is 
conspicuously absent from the debate. The recently decided case 
invalidating Myriad’s BRCA1/2 patents, however, arguably 
opened the door to a more nuanced application for genetic 
exceptionalism: invalidating gene patents based primarily on a 
gene’s unique function in nature as an information carrier. To 
better understand how Judge Sweet’s legal analysis effectively 
directs gene patents down the road to exceptionalism, it is first 
92 Id. 
93 Because this Article focuses solely on genetic exceptionalism’s influence 
on the subject matter requirement for gene patents, the court decisions regarding 
utility, novelty, obviousness, and enablement will not be discussed here. 
Recognizing these requirements are equally important to gene patentability, the 
Author suggests reading Lauren M. Nowierski, Note, A Defense of Patenting 
Human Genome Sequences Under U.S. Law: Support For the Patenting of 
Isolated and Purified Substances, 26 CARDOZO ARTS & ENT. L.J. 473 (2008), 
for an in-depth overview of genetic patent challenges under these patentability 
prongs. See also Conley, supra, note 40. 
94 See, e.g., Sonia M. Suter, The Allure and Peril of Genetics 
Exceptionalism: Do We Need Special Genetics Legislation?, 79 WASH. U. L.Q. 
669, 671 (2001). 
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necessary to understand the principle of genetic exceptionalism 
and its historical development in American culture. 
Genetic exceptionalism is a term that refers to the idea that 
genetic information is qualitatively different from other health 
information and raises separate social, ethical, and legal issues.95 
Both a fascination with the inherent power of genetic information 
and the historical fear from genetics’ role in eugenics arguably 
spawned the principle of genetic exceptionalism.  
Despite its potential for providing improved patient care, 
genetic information can be both “uniquely threatening and 
susceptible to misuse.”96 In an article assessing its allure, Professor 
Sonia M. Suter traced genetic exceptionalism’s development from 
its historical roots through the eyes of four key stakeholders: the 
public, the media, scientists, and policy makers.97 Since the 
discovery of genes, the public and media have together elevated 
genes’ status to an arguably overstated position of the “Holy Grail” 
of predictive traits and patient well-being. Since the early 1960s, 
the media has run rampant with coverage that suggests single 
genes alone determine characteristics ranging from everything like 
aggression to homosexuality, while often understating the role of 
multi-gene and environmental interactions.98 
In the 1980s, popular culture was fixated on the advent of gene 
therapy that promised to treat or prevent disease altogether, but 
three decades later the public and medical community are still 
95 Id. at 671. 
96 Id. 
97 Id. at 674-75. 
98 See, e.g., Robert Wring, Our Cheating Hearts, TIME MAGAZINE, Aug. 15, 
1994 (“[Genes] affect behavior by creating feelings and thoughts--by building 
and maintaining the brain.”); DOROTHY NELKIN & M. SUSAN LINEE, THE DNA 
MYSTIQUE: THE GENE AS A CULTURAL ICON 85 (1995) (quoting a New York 
Times reporter as having said “evil is ‘embedded in the chromosomes that our 
parents that our parents pass to us at conception.’”). In their book, authors 
Nelkin and Linee suggest that popular culture’s “love affair” with the gene 
draws from scientific principles, but fails to confine itself to DNA’s technical 
boundaries. The authors detailed the debate over the criminal gene, which 
gained traction in the early 1960s and continued throughout the decades in 
media’s coverage of seemingly unexplainable crimes. See id. at 83-86. 
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waiting for the promise to come to fruition.99 As one author 
comments, “Science reporters must first and foremost attract 
readers, a difficult task when competing with more attention-
grabbing topics like war and pop culture. Likely in response to this 
pressure, two trends have emerged in media coverage of genetics: 
oversimplification and sensationalism.”100 
Prior to 1993, media coverage focused on newly discovered 
genes, but as these discoveries became “old news,” the stories lost 
their luster.101 The media responded by shifting their angle to the 
pitfalls and perils of genetics, reporting on cautionary tales of 
discrimination and the proliferation of designer babies.102 
Regardless of whether the undulating media coverage currently 
paints genetics with a brush or negative, the public’s impression 
that genetics deserves a unique, tailored discourse has already been 
solidified in the collective mind. 
Throughout the ongoing discourse, the public and media have 
not ignored the other side of the proverbial genetic coin. 
Simultaneous with genetics’ elevation to its “Holy Grail” status 
was the emergence of a historically-based distrust of genetics’ 
misuse. While the majority of the public most readily identifies the 
eugenics movement’s apex with the Nazi experiments of World 
War II, the principles of reproductive selection have existed since 
the days of Darwin.103And as evidenced by the oft-reviled United 
99 See Gene Therapy, HUMAN GENOME PROJECT INFORMATION (Aug. 24, 
2011), http://www.ornl.gov/sci/techresources/Human_Genome/medicine/ 
genetherapy.shtml. Gene therapy remains in the experimental stage and has yet 
to have a solidly successful clinical trial. The technology has not overcome the 
difficulties presented by the short-lived nature of gene therapy, immune 
responses in recipients, problems with viral vectors, and the complex nature of 
multigene disorders. 
100 Ellen Dupont, Diagnosing the Geno-Hype: Genetic Determinism in the 
Mass Media, 5 THE SCI. IN SOC’Y REV. 20, 21 (Spring 2009). 
101 Suter, supra note 94, at 678 n.1. 
102 See Dupont, supra note 100; see also David A. Hyman, Lies, Damned 
Lies and Narrative, 73 IND. L.J. 797 (1998) (discussing the power of anecdotal 
evidence to shape public opinion); Mike Snider, How Genetics Can Be Used 
Against You, USA TODAY, Nov. 17, 1993, at 9D, available at 1993 WL 
6726460; Lisa Goldstein, If You Knew Your Child Would Be Born Deaf, S.F. 
CHRON., Feb. 1, 1999, at A19. 
103 Although deemed most prolific implementation of eugenics practice, the 
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States Supreme Court case Buck v. Bell,104 the eugenics movement 
did not culturally confine itself. In fact, eugenics’ principles 
manifested themselves as the underpinning rationale for the 
Court’s upholding of compulsory sterilization in America.105 Not 
only did courts promulgate eugenics principles, so too did the 
legislatures at both the federal and state level. In 1924, Congress 
adopted the Federal Immigration Restriction Act to curb the 
migration of persons thought to have defective genes.106 States, on 
the other hand, began implementing mandatory genetic screening 
programs for African Americans in the 1970s, resulting in the 
unintended, yet harmful stigmatization of the African American 
population.107 This brief history of the eugenics movement serves 
only to illustrate the imbedded distrust present in the public’s 
perception of genetic science. 
Many scholars, researchers, and law makers alike have been 
influenced by the media and the history of genetics as an 
exceptional science in their quest for solutions to social issues and 
policy making. As early as the 1970s, legislatures have crafted 
laws that regulate genetic information separate and apart from 
other medical information,108 the most recent genetic-specific 
legislation being the Genetic Information Nondiscrimination Act 
signed into law by President Bush in 2008.109 Contributing to the 
Nazi regime by no means created the practice. The word “eugenics” was coined 
in 1883 by Francis Galton to refer to the practice of improving the human race 
by controlling reproduction. Martin S. Pernick, Eugenics and Public Health in 
American History, 87 AM. J. PUB. HEALTH 1767 (1997). In 1922, the American 
Society for Eugenics was founded in the United States to “stem the tide of 
threatened race degeneracy,” and in 1927, the Supreme Court of the United 
States justified the use of compulsory reproductive eugenics to sterilize those 
deemed unfit for reproducing. Id. at 1769. 
104 274 U.S. 200 (1927). 
105 See id. 
106 Paul Lombardo, Medicine, Eugenics, and the Supreme Court, 13 J. 
CONTEMP. HEALTH L. & POL’Y 2 (1996). 
107 Howard Markel, The Stigma of Disease: Implications of Genetic 
Screening, 93 AM. J. MED. 209, 210-11 (1992). 
108 Suter, supra note 94 at 670 n.1.  
109 Genetic Information Nondiscrimination Act, H.R. 493 (110th Cong. 
2008). GINA prohibits health insurance companies and employers from 
discriminating against individuals based on genetic information, which includes 
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driving force of the exceptionalism movement was the dedication 
of “the largest expenditure of money for biomedical ethics and 
health law in the country” to the study of the ethical, legal, and 
social issues (ELSI) in genetic research.110 This unprecedented 
expenditure generated a vast body of literature and countless 
studies dedicated exclusively to genetic issues, and “even if much 
of the scholarship is not explicitly premised on notions of genetics 
exceptionalism, . . . [it] intensifies the media’s attention to genetics 
issues and public fear about genetics.”111 While many of the same 
threats for misuse and potential social consequences exist in other 
disciplines, no other science has captivated the public with equal 
pervasiveness as genetic science.112 
The confluence of lofty promises for cures, the trendy appeal 
of the ethical issues, and the sordid history of misuse can explain 
genetic exceptionalism in American culture. Traditionally, scholars 
have analyzed genetic exceptionalism in the areas of employment 
discrimination, insurance discrimination, and privacy laws.113 The 
family medical histories and information pertaining to an individual or family 
member’s genetic tests and genetic services. Although several states had already 
acted to protect against genetic discrimination, GINA served to set the minimum 
level of protection afforded to individuals. 
110 Suter, supra note 94, at 685 n.1 (quoting Robert Weir, Why Fund ELSI 
Projects?, in GENES AND HUMAN SELF KNOWLEDGE: HISTORICAL AND 
PHILOSOPHICAL REFLECTIONS ON MODERN GENETICS 189 (Robert F. Weir et al. 
eds., 1994)). 
111 Suter, supra note 94, at 685-86. 
112 See Thomas H. Murray, Genetic Exceptionalism and “Future Diaries”: 
Is Genetic Information Different from Other Medical Information, in GENETIC 
SECRETS: PROTECTING PRIVACY AND CONFIDENTIALITY IN THE GENETIC ERA 60, 
61 (Mark A. Rothstein ed., 1997); Suter, supra note 94. But see Eric T. Juengst, 
FACE Facts: Why Human Genetics Will Always Provoke Bioethics 32 J.L. MED. 
& ETHICS 267 (2004) (arguing that genetic information’s intrinsic moral value 
justifies the continued prominence of genetic exceptionalism in bioethics). 
113 See Suter, supra note 94; see also Trudo Lemmens, Selective Justice, 
Genetic Discrimination, and Insurance: Should We Single Out Genes in Our 
Laws?, 45 MCGILL L.J. 347 (2000) (discussing the desirability of genetic-
specific legislation in the insurance context); Douglas H. Ginsburg, Genetics 
and Privacy, 4 TEX. REV. L. & POL. 17 (2000); Mark A. Rothstein, Genetic 
Exceptionalism and Legislative Pragmatism, 35 J.L. MED. & ETHICS 59 (2007); 
Lawrence O. Gostin & James G. Hodge, Jr., Genetic Privacy and the Law: An 
End to Genetic Exceptionalism, 40 JURIMETRICS J. 21 (1999) (arguing that there 
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literature is silent, however, on whether genetic exceptionalism 
applies with equal force to the patentability of genes debate. In 
other words, assuming that the statutory requirements for 
patentability can otherwise be satisfied, should the law reject gene 
patents based solely on genetic exceptionalism’s justification that 
genes unique characteristics warrant different protections than do 
other fields of science?  
 
B.  Power Play from the Bench: Myriad’s Insertion of Genetic 
Exceptionalism into the Patent Act 
 
The previous sections provide background information to the 
reader with regard to the law on gene patents and the story of 
genetic exceptionalism’s impact on insurance, discrimination, and 
privacy laws. In the recent controversial case on gene patents, 
Association for Molecular Pathology v. U.S. Patent and 
Trademark Office,114 patentable subject matter collides with 
genetic exceptionalism for the first time, transforming genetic 
exceptionalism into a legal principle. In the opinion, Judge Sweet 
singles out DNA from other isolated products based purely on 
DNA’s information carrying characteristics, while attempting to 
invalidate DNA patents under a “product of nature” analysis.115 
The court falls short in its explanation of why other purified or 
isolated products of nature continue to be patentable subject 
matter. Perhaps influenced by DNA’s mystique, the court reasoned 
that genetic patents differ from patents on antibodies, antibiotics, 
hormones, metabolites, biologic drugs, and the like, because DNA 
is solely the “physical embodiment of information.”116 Rather than 
purely focusing on the chemical makeup of DNA (after all, DNA is 
comprised of chemically bound strands of molecules), the court 
is no clear demarcation between genetic data and other health information). 
114 702 F. Supp. 2d 181 (S.D.N.Y. 2010); referred to herein as “Myriad.” 
115 See id. 
116 See Noonan, supra note 44, at 30 n.17. As Noonan points out, these 
naturally occurring, isolated products are in “substantially homogenous form, 
are structurally unchanged from their sources in blood and other bodily fluids, 
and are less altered than the cDNAs that are the subject of the claims to isolated 
human DNA invalidated by the district court.” Id. 
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embraces the genetic exceptionalism ideals by finding that genes 
are inherently different and thus deserving of unique treatment 
under the Patent Act.117 Despite whether genetic information 
should be treated differently in other contexts—for example with 
insurance, discrimination, and privacy laws—Judge Sweet 
overlooks the fact that the genetic information itself is not 
patented. As such, researchers are able to utilize the genetic 
information disclosed in the patent for purposes such as 
performing sequence comparisons or detecting genetic 
polymorphisms.118 This section dissects the law on patentable 
subject matter from the opinion’s genetic exceptionalism 
components, and then evaluates whether the holding can stand 
based purely on the legal arguments that remain. 
 
1. Background of BRCA1/2 and the Myriad Litigation 
 
In 1990, a team of geneticists discovered that a mutation in the 
BRCA1 gene was linked to an increased risk for developing breast 
and ovarian cancers.119 Of the patients with hereditary breast 
cancer, five to ten percent have a substituted allele that inactivates 
the BRCA1 gene, leading to an abnormal cellular gene expression 
of the protein.120 If a patient has a mutated gene, she has a lifetime 
risk of 40 to 85 percent for developing breast cancer and a risk of 
16 to 40 percent for developing ovarian cancer.121 Other known 
factors, such as the type of mutation (e.g., insertion, deletion, or 
rearrangement of codons) and family history can impact the 
lifetime risk of developing cancer, as well as the likely interaction  
 
117 Some philosophers have viewed genes as more than the “common 
heritage of mankind,” arguing that genes are an “un-encloseable commons-by-
necessity . . . . free for use by any and all.” David Koepsell, Naturally Occurring 
Genes and the Commons by Necessity, 23 GENEWATCH 32, 34 (Oct.-Dec. 2010). 
118 Id. at 31. 
119 Bryn Williams-Jones, History of a Gene Patent: Tracing the 
Development and Application of Commercial BRCA Testing, 10 HEALTH L.J. 
123, 131 (2002). 
120 Id. at 127. 
121 Id.  
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with other genes.122 The BRCA2 gene is also thought to be a 
similar acting tumor-suppressing gene.123 
Mark Skolnick, the co-founder of Myriad, sequenced the 
BRCA1 gene in August 1994 with the help of a team of 
researchers from NIH, the University of Utah, and McGill 
University.124 Following this discovery, Skolnick and Myriad filed 
for a U.S. patent claiming the isolated sequence and the associated 
mutations as both a “composition of matter” and a “method-of-
use.”125 The USPTO was quick to issue the patents to Myriad, but 
further complicated the patentability of BRCA1 by issuing a 
similar patent to OncorMed.126 OncorMed’s BRCA1 patent 
differed only slightly with respect to the mutations claimed, 
overlapping in both the diagnostic and therapeutic applications of 
the patent.127 As a result, both patent owners filed infringement 
suits against the other, but instead of litigating the issue, 
OncorMed settled by selling Myriad its patent on BRCA1 in 
1998.128 
Understanding the importance of locating and patenting 
BRCA2, Myriad embarked on a race to discovery against a group 
of U.K. scientists who were also highly invested in locating the 
sequence. On December 21, 1995, the day before the U.K. 
scientists were scheduled to publish its discovered BRCA2 
sequence in Nature magazine and the day of the U.K.’s planned 
press conference, Myriad notified the public that they had 
sequenced BRCA2 and had filed for a U.S. patent.129 Having now 
secured patents to both the isolated BRCA1 and BRCA2 genes, 
Myriad was poised to control the testing market for breast and 
122 Id. 
123 Id. 
124 Id. at 131. The founders of Myriad were “focused on the discovery and 
commercialization of genes involved in major common disorders including 
cancer and heart disease.” Id. at 129 (citation omitted). Myriad now offers an 
array of services, ranging from research and development to diagnostics.  
125 Id. 
126 Id. at 132. 
127 Id. 
128 Williams-Jones, supra note 119, at 132. 
129 Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 202 
(S.D.N.Y. 2010). 
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ovarian cancer and the market for developing therapeutics to treat 
patients with one of the mutations.130 
Over the course of the 1990s, Myriad did not assert its 
exclusivity rights over its BRCA1/2 patents, but instead allowed 
researchers to use the tests under certain circumstances. Myriad 
offered to license its patents to the University of Pennsylvania 
Genetic Diagnostic Laboratory so that the laboratory could 
continue its screening program on BRCA1 and BRCA2.131 Not 
satisfied with the scope of the license, the University and its 
physicians rejected the licensing proposal.132 Myriad subsequently 
sent cease-and-desist letters to the University of Pennsylvania and 
on August 26, 1998, sent notice that the physicians were infringing 
Myriad’s patents and filed the infringement suit in November of 
the same year.133 Although the laboratory was forced to stop 
performing tests, Myriad informed the University that it was free 
to continue academic research on the genes.134 A similar course of 
conduct—Myriad offering a license and the plaintiffs rejecting the 
license—occurred with the other plaintiffs in the case.135 
Myriad asserted seven patents against the plaintiffs, identifying 
fifteen claims within those patents that the plaintiffs allegedly 
infringed.136 The claims fell into one of two categories: 
composition claims or method-of-use (or process) claims.137 
Because there were several composition claims within the patent, 
130 In the years following the issuance of the patents, Myriad developed a 
host of tests to screen and diagnose patients with an increased risk for breast 
cancer. Among the tests (listed from least to most expensive) include: (1) a 
single site test for patients having a family history of the mutation, designed to 
identifies carriers; (2) a multisite test that searches for three common mutations 
in the Ashkenazi Jewish population; (3) a comprehensive test identifying the full 
gene sequence; and (4) a rapid test designed to return the full gene sequence 
within seven days. Williams-Jones, supra note 119, at 133-34. Myriad’s tests 
were arguably more sensitive than other tests offered at the time because 
Myriad’s tests identified each base-pair within the gene. Id. 





136 Id. at 212. 
137 Id. 
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the court provided one composition claim as the categorical 
representative, which read: “An isolated DNA coding for a BRCA1 
polypeptide, said polypeptide having the amino acid sequence set 
forth in SEQ ID NO:2.”138  
Similarly, the court provided a representative methods-of-use 
claim for Myriad, which reads: “A method for detecting a germline 
alteration in a BRCA1 gene . . . in a human which comprises 
analyzing a sequence of a BRCA1 gene or BRCA1 RNA from a 
human sample or analyzing a sequence of BRCA1 cDNA . . . .”139 
In layman’s terms, the first category of claims at issue covers any 
use of the isolated gene itself and the second category of claims at 
issue covers methods used to analyze mutations in the gene that 
correlate with a predisposition for breast and ovarian cancer.140  
The plaintiffs brought an action for summary judgment against 
the USPTO & Myriad asking the court to declare these patents 
relating to BRCA1/2 invalid for lack of patentable subject 
matter.141 The plaintiffs urged the court to find that the patents 
were improperly issued to cover products of nature, laws of nature, 
physical phenomena, and abstract ideas, which offend Article I,     
§ 8, Clause 8 of the United States Constitution.142 
 
2. A Closer Look at Judge Sweet’s Analysis in the Myriad 
Decision 
 
Judge Sweet crystallized the issue before the court as whether 
“isolated human genes and the comparison of their sequences [are] 
patentable.”143 He embarked on his legal inquiry by first 
constructing the claims at issue to determine the scope of the 
patent protection. The first claim dispute to be resolved involved 
the terms “DNA” and “isolated DNA.”144 The plaintiffs argued 
138 Id. (emphasis added). 
139 Id. at 213 (emphasis added). 
140 See id. at 211-17. 
141 Id. at 184. 
142 Id.  
143 Id. at 185. 
144 Id. at 216. In construing a patent claim, the court applies several cannons 
of construction to arrive at a final interpretation. These canons can be broken 
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that the term “DNA” should be construed to mean “a sequence of 
nucleic acids, also referred to as nucleotides.”145 As Myriad 
pointed out, this definition implies that DNA refers to a description 
of the sequence of nucleic acids (i.e., information only).146 Myriad 
contended that “DNA” encompasses a “real and tangible molecule, 
a chemical composition made up of deoxyribonucleotides linked 
by a phosphodiester backbone.”147 In resolving this dispute in 
Myriad’s favor, the court looked at the specification of Myriad’s 
patent, which explicitly referred to DNA as a physical 
manifestation of the nucleotides such that the DNA could be 
separated from the other components of the cells that naturally 
accompany DNA.148 Similarly, the court adopted Myriad’s 
definition of “isolated DNA” as set forth in the specification, 
which defined isolated DNA as “a DNA molecule which is 
substantially separated from other cellular components which 
naturally accompany a native human sequence . . . .”149 
The second claim concerned the definition of BRCA1 and 
BRCA2. The plaintiffs argued that each meant “a particular 
fragment of DNA found on chromosome 17 [13 for BRCA2] that 
relates to a person’s predisposition to develop breast and ovarian 
cancer.”150 Once again, however, Myriad acted as its own 
lexicographer, defining in the patent specification each gene as “a 
human breast cancer predisposing gene . . . some alleles of which 
down into two categories, intrinsic and extrinsic evidence, with more weight 
given to the former. Some of the intrinsic evidence considered by a court 
includes: words of the claims themselves, the written description, and the 
prosecution history of the patent. Id. at 214-15. In looking at this evidence, the 
court will not read a limitation in a dependent claim into the independent claim, 
nor will the court read a limitation from the specification into the claim (but 
does read the claim “in light of” the specification). Finally, if the patentee acts as 
its own “lexicographer,” then the court will use the patentee’s definition for a 
disputed term. The court may also look at the extrinsic evidence available: 
dictionaries, treatises, and expert testimony. Usually, extrinsic evidence is used 
to inform the judge of the field of science and technology. Id. at 215-16. 
145 Id. 
146 See id. 
147 Id. 
148 Id. at 216. 
149 Id. at 217. 
150 Id. 
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cause susceptibility to cancer, in particular breast and ovarian 
cancer.”151 While noting that BRCA1 and 2 are genes normally 
integrated into chromosomes 17 and 13 respectively, the court 
again adopted Myriad’s construction of the definition.152 
Having construed the claim language, the court moved into the 
heart of the analysis: subject matter patentability under § 101 of 
the Patent Act, which provides, “Whoever invents or discovers any 
new and useful process, machine, manufacture, or composition of 
matter, or any new and useful improvement thereof, may obtain a 
patent . . . .”153 Although Congress intended to grant patent 
protection broadly, § 101 is not without limits. Specifically, the 
Supreme Court has carved out three categories of non-patentable 
subject matter: laws of nature, natural phenomena, and abstract 
ideas. The reasoning behind these exclusions is that although each 
may be “discovered” in a sense, each comprises the basic tools of 
science and technological work.154 
Under the heading, “Patentable subject matter must be 
‘markedly different’ from a product of nature,” Judge Sweet 
emphasized that questions of utility and statutory subject matter 
patentability are wholly separate inquiries, and only cases decided 
on subject matter grounds are binding on the court.155 Judge Sweet 
relied on Funk Brothers, which he described as holding that the 
mixture of bacteria was not patentable subject matter because it 
“did not create a state of inhibition or of non-inhibition,” but rather 
maintained qualities that were a work of nature.156 Despite ample 
151 Id. 
152 Id. 
153 Id. at 218 (emphasis added). 
154 Id. at 218-219 (citing Diamond v. Chakrabarty, 447 U.S. 303, 309 
(1980)). Recall from discussion supra, Chakrabarty held that a genetically 
altered bacterium was patentable subject matter because it had “markedly 
different characteristics from any found in nature and one having the potential 
for significant utility.”  
155 Id. at 219, 222. 
156 Id. (citing Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127, 
128-31 (1948)). Recall that Funk Brothers was deciding the issue whether the 
mixture was an “invention or discovery,” not necessarily whether the mixture 
was patentable subject matter. Prior to the Patent Act of 1952, “invention or 
discovery” was interpreted as the non-obvious prong for patentability. See Brief 
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evidence that Funk Brothers was decided on grounds other than 
subject matter patentability,157 however, the court interpreted the 
case as standing for the exclusion of natural phenomena from 
subject matter patentability.158  
The court next turned in passing to Chakrabarty, which is 
arguably more controlling in Myriad since it was decided under     
§ 101 of the current Patent Act.159 While he included some of the 
language of the opinion, Judge Sweet omitted any meaningful 
discussion on the analysis underlying the Court’s holding. For 
instance, he seemingly glossed over the part of the Chakrabarty 
opinion that states that without a specifically designed exception 
from Congress, § 101 should be construed broadly and in such a 
way that includes living things.160 Since the decision, Chakrabarty 
has supported patenting living products that have “markedly 
different characteristics from any found in nature and one having 
the potential for significant utility.”161 
Throughout the next several pages of the Myriad opinion, 
Judge Sweet proffered a litany of cases that essentially require 
“something more” than merely isolating or purifying a substance 
from its native state to fall within the scope of statutory subject 
matter.162 Read collectively, these cases require that a patentable 
product have qualities or characteristics that were absent in its 
for Alnylam Pharmaceuticals, Inc. as Amici Curiae Supporting Defendants-
Appellants, Ass’n for Molecular Pathology v. Myriad Genetics, Inc. 133 S.Ct. 
694 (2012) (No. 12-398) at 8 (“Debunking myths of Funk Bros. Seed Co. v. 
Kalo Inoculant Co.”), available at http://patentdocs.typepad.com/files/alnylam-
amicus-brief.pdf. There is ample language in the Funk Brothers opinion that 
suggests the mixture was not patentable because the proffered “invention” 
conferred no new quality or use (i.e., obvious) for any one bacterium in the 
mixture or for the collective whole. Rather, the mixture merely provided 
consumers with a more convenient way to purchase the component bacteria. 
157 See id.  For a discussion on this very issue, visit the 37 Thoughts legal 
blog, available at http://37thoughts.wordpress.com/2010/03/30/save-the-funk-
brothers/.  
158 Myriad, 702 F. Supp. 2d at 222. 
159 Id. at 223. 
160 Chakrabarty, 447 U.S. at 318. 
161 Id. at 310. 
162 Myriad, 702 F. Supp. 2d at 223-28. 
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natural form.163 As examples, the court cited to refined cellulose, 
artificial alizarine dye, purified tungsten, and isolated pine needle 
fibers, all of which were rejected as non-patentable subject 
matter.164  
Turning to precedent relied on by Myriad, Judge Sweet 
summarily rejected the applicability of Parke-Davis, which Myriad 
asserted as establishing that the purification of a naturally 
occurring product (i.e., adrenaline) was patentable subject 
matter.165 He noted that Parke-Davis was decided on novelty—not 
subject matter—grounds and was therefore not applicable to the 
present case being decided under § 101.166 In so doing, he cast the 
language in Parke-Davis, which stated that “even if [adrenaline] 
were merely an extracted product without change, there is no rule 
that such products are not patentable,” as dicta.167 Judge Sweet 
went on to distinguish other cases cited by Myriad based on similar 
reasoning.168 
Finally, almost as an afterthought, Judge Sweet briefly 
addressed Merck & Co., Inc. v. Olin Mathieson Chem. Corp.,169 
which held that a higher concentration of purified Vitamin B12—
capable of treating anemia—was a patentable composition of 
matter.170 The purified B12 was created through an artificial 
fermentation process that allowed for the production of a greater 
concentrated product than the naturally occurring B12 produced by 
cows.171 Because of the different concentration and effectiveness 
as a therapeutic agent, the Mathieson court reasoned that the new 
product was not the same as the old naturally occurring product, 
but rather a “new and useful composition entitled to the protection 
163 See id. 
164 See id. 
165 See id. at 225. 
166 Id at 225-26. 
167 Id. at 226 (quoting Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95, 
103 (S.D.N.Y. 1911)). 
168 Id. at 225-27. 
169 253 F.2d 156 (4th Cir. 1958). 
170 Myriad, 702 F. Supp. 2d at 227. 
171 Mathieson, 253 F.2d at 165. 
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of the patent.”172 Without scratching the surface of the case, Judge 
Sweet merely pointed out the court’s conclusion that purified 
Vitamin B12 was more than a “mere advance in the degree of 
purity of a known product.”173 
 
3. Genetic Exceptionalism Transcribed into Legal Principle: 
Isolated DNA is not “Markedly Different” from Native DNA 
 
After setting forth the legal precedent, Judge Sweet identified 
the applicable test for determining the subject matter patentability 
of Myriad’s isolated BRCA1 and BRCA2 gene patents. Namely, 
whether the isolated DNA claimed in the patent possesses 
“markedly different characteristics” from the native (or genomic) 
DNA.174 Focusing on the chemical make-up of DNA, Myriad 
argued that the isolated DNA is markedly different because it 
differs both structurally and functionally from genomic DNA.175 
Instead of looking at the similarities and the differences between 
the two compositions, Myriad argued the court should look 
exclusively at the differences.176 Judge Sweet rejected this 
approach, citing Supreme Court precedent that requires claims be 
considered as a whole.177 While a correct statement of the law, the 
law may be misapplied; reading the claim as a whole means 
looking at the entire claim regarding isolated DNA, not the 
genomic DNA that falls outside the scope of the patent.178 
At this point in the opinion, Judge Sweet diverges from a 
purely legal argument into what is viewed by some as carving out 
an exception for gene patents based on the inherent information 
carrying function of genes themselves. He explained that focusing 
on the chemical nature of DNA “fails to acknowledge the unique 
characteristics of DNA that differentiate it from other 
172 Id. 
173 Myriad, 702 F. Supp. 2d at 227 (quoting Mathieson, 253 F.2d at 164). 
174 Id. at 227-28. 
175 Id. at 229. 
176 Id. 
177 Id.  
178 See id. at 228. 
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compounds.”179 Without citing any legal authority justifying why 
DNA should be considered differently under the Patent Act, he 
goes on to explain that even if other chemical compounds contain 
information, the information encoded in DNA reflects its primary 
biological function: “[DNA] direct[s] the synthesis of . . . proteins, 
biological molecules of enormous importance, which catalyze 
biological chemical reactions and constitute the major structural 
materials of the animal body.”180 Thus, DNA could be seen as the 
“physical embodiment of laws of nature.”181 
Given the unique nature of DNA, Judge Sweet reasoned that 
the structural and functional differences raised by Myriad were not 
“markedly different.”182 Rather than explaining why the 
differences are not relevant to an inquiry into the nature of native 
versus isolated DNA, he jumped to the conclusion that neither is 
relevant because of the “overriding importance of DNA’s 
nucleotide sequence to both its natural biological function as well 
as the utility associated with DNA in its isolated form.”183 In other 
words, because isolated DNA preserves the important 
characteristics of native DNA, isolated DNA can never be 
“markedly different.”184 He goes on to state that the “defining 
characteristic of DNA in its native and isolated forms mandates the 
conclusion that the challenged composition claims are directed to 
unpatentable products of nature.”185 
In its attempt to persuade the court, Myriad delineated several 
distinctions between isolated DNA and native DNA. First, they 
argued, there are structural differences because isolated DNA is 
179 Id. In response to biotech’s assertion that invalidating gene patents will 
lead to invalidating pharmaceuticals, Judge Sweet states: “The conclusions 
reached in this opinion concerning the subject matter patentability of isolated 
DNA . . . are based on the unique properties of DNA that distinguish it from all 
other chemicals and biological molecules found in nature.” Id. at 228 n. 51 
(emphasis added). 
180 Id. (internal quotations omitted). 
181 Id. 
182 Id. at 229. 
183 Id.  
184 See id. 
185 Id. (emphasis added). 
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not associated with chromosomal proteins.186 The court rejected 
this argument, stating it was only a matter of purity.187 Next, 
Myriad asserted that native DNA contains introns (noncoding 
regions) that are absent from the isolated or purified DNA, which 
only contains the exons (coding regions).188 However, Judge Sweet 
found that because the isolated DNA contains some of the same 
gene fragments (e.g., the same fifteen nucleotide sequence), the 
two are not sufficiently different.189 Judge Sweet stated that the 
claims covering the compositions of matter for BRCA1/2 (i.e., 
cDNA molecules) cover the same product that is produced by 
naturally-occurring splicing within the cell.190 Yet he failed to 
recognize that the isolated DNA—as a chemical molecule—is 
much smaller, not three dimensional, and lacks the chemical 
complexity of genomic DNA, all properties which permit novel 
and innovative uses.191 
Arguably, Myriad’s strongest argument rested with isolated 
DNA’s ability to be practically applied in ways that native DNA 
cannot. By extracting and significantly altering native DNA, 
scientists are able to use the isolated molecules to improve patient 
health care.192 With the adapted DNA, scientists are able to 
perform diagnostic tests using the molecule as a probe, primer, or 
template for sequencing genes.193 Likewise, isolated DNA opens 
the door to medical treatment options ranging from preventative 
care to gene therapy.194 Without the isolated DNA molecules, none 
of these health care innovations would be possible.195 
186 Id. at 228-29. 
187 Id. at 229. 
188 Id. at 230. 
189 Id.  
190 Id. at 229-230. 
191 See Brief for Am. Intellectual Prop. Law Ass’n as Amici Curiae 
Supporting Neither Party, Ass’n for Molecular Pathology v. USPTO, 653 F.3d 
1329 (Fed. Cir. 2011) (No. 2010–1406) at 14, available at http://www.aipla.org/ 
Advocacy%20Shared%20Documents/AIPLA-Myriad-Amicus-filed.pdf 
[hereinafter “AIPLA Brief”]. 
192 Id. 
193 Id.  
194 Id. 
195 Id. at 14-15. 
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Finally, Judge Sweet hypothesized that a “time may come 
when the use of DNA for molecular and diagnostic purposes may 
not require such purification.”196 This consideration runs contrary 
to patent law, which requires the evaluation for patentability to 
take place at the time of the invention, regardless of any 
subsequent innovations.197 
Notwithstanding the newly derived capabilities of isolated 
DNA, the court erroneously rejected these differences, instead 
electing to focus on the information carrying characteristics of 
inherent in the nucleotide sequence. In so doing, Judge Sweet 
elevates DNA to a greater status than other chemical molecules—
excepting genetic science from other fields of discovery. There is 
nothing in precedent or the Patent Act that demands DNA be 
treated differently than the molecules which comprise it. It follows 
that if Judge Sweet had not cast DNA as an elite chemical 
substance, the decision may have fallen more in line with that of 
the Court of Customs and Patent Appeals in In re Bergy.198  
In Bergy, the court was presented with the question whether the 
discovery of a biologically pure bacterium for pharmaceutical use, 
providing an indispensable medical tool, was patentable.199 The 
court reasoned, 
[M]icroorganisms have long been important tools in 
the chemical industry, especially its pharmaceutical 
branch, and when such a useful, industrial tool – 
[the tools used by chemical manufacturers in the 
same way as they use chemical elements, 
compounds, and compositions] – is invented which 
is new and unobvious, so that it complies with those 
conditions for patentability, we see no reason to 
deprive it or its creator or owner of the protection 
196 Myriad, 702 F. Supp. 2d at 232. 
197 See 35 U.S.C. § 103 (stating the time for evaluating obviousness against 
prior art is at the time of invention, not the time of the patent application’s 
evaluation). 
198 596 F.2d 952 (C.C.P.A. 1979) (affirmed sub nom Diamond v. 
Chakrabarty, 447 U.S. 303 (1980)). 
199 Id. 
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and advantages of the patent system by arbitrarily 
excluding it at the outset from the § 101 categories 
of patentable invention on the sole ground that it is 
alive. It is because it is alive that it is useful. . . .200 
By analogy, DNA’s chemical characteristics enable it to be 
used as a medical tool, but not unless it is isolated and purified. 
Without the man-made changes, the DNA molecule is unable and 
unreliable as a diagnostic tool. Thus, neither law nor fact supports 
arbitrarily excluding isolated DNA from patent protection owing to 
the fact that it carries the same information as genomic DNA. As 
an Amicus Curie brief eloquently summarized, “By selectively 
assigning dispositive importance to one shared characteristic of the 
claimed purified/isolated DNA molecules and discounting all the 





After reviewing Judge Sweet’s 152-page opinion, the Author 
would argue that there is no legal or factual basis for declaring 
isolated DNA outside the scope of patentable subject matter. 
Instead, it appears that the impetus behind the Myriad decision is 
rooted in genetic exceptionalism. By adhering to the principles of 
genetic exceptionalism, the opinion tends to overlook legal 
precedent to arrive at a conclusion that the nature of DNA as 
information carriers naturally exempts itself from patent protection 
absent an express exclusion from Congress. One could conclude 
that the Myriad decision was largely influenced by the societal, 
moral, and ethical issues—not by the legal precedent—raised by 
the plaintiffs. The opinion devoted several pages to the negative 
impacts that gene patents have on costs and access to health care as 
well as the possible chilling effect on research innovation. While 
these are important considerations in determining patent policy, 
they are not factors to be applied under the Patent Act. If such was 
the case, patented and statutorily permissible subject matter—such 
200 Id. at 975 (emphasis added) (internal citations and quotations omitted). 
201 AIPLA Brief at 17 (citing Bergy, 596 F.2d at 975). 
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as pharmaceuticals example—could be invalided solely based on 
similar policy concerns. Whether one agrees that genetic 
information should be treated different, almost reverently, deciding 
whether to adopt genetic exceptionalism is a matter of public 
policy rather than legal principle.202 Thus mandating that the 
Patent Act subject matter patentability requirement be interpreted 
through the lens of genetic exceptionalism is a power not conferred 
to the bench, but rather to Congress. 
  
202 Perhaps Chief Justice Burger stated it best in Chakrabarty, when 
addressing the judicial branch’s place in making policy decisions:  
The choice we are urged to make is a matter of high policy for 
resolution within the legislative process after the kind of 
investigation, examination, and study that legislative bodies 
can provide and courts cannot. That process involves the 
balancing of competing values and interests, which in our 
democratic system is the business of elected representatives. 
Whatever their validity, the contentions now pressed on us 
should be addressed to the political branches of the 
Government, the Congress and the Executive, and not to the 
courts. 
447 U.S. at 317. 
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